Current Research Studies
Cancer – AHOD1721: A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Condition or Therapy:
Cancer and Blood Disorders
Study Number: AHOD1721
What is the goal of this study?
The aim of this study is to find out how well the study drugs, nivolumab, brentuximab vedotin and bendamustine, work in children and adolescents with classic Hodgkin Lymphoma. The purpose is also to look at the safety and side effects in this group of patients.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are between 5 and 30 years of age and
- Have classical Hodgkins Lymphoma (cHL), excluding nodular lymphocyte-predominant cHL, after failure of or non-response to first-line therapy and
- Have not previously received an allogeneic and/or ASCT for cHL and
- Have no prior exposure to anti-PD1, anti-PDL1, anti-PD-L2, anti CD137, or anti-CTLA-4 antibodies, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Participants who are older than 16 must have a Karnofsky performance level greater than or equal to 50%.
Participants who are 16 or younger must have a Lansky performance level greater than or equal to 50.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.